Navigation Links
Lapatinib shows minimal effect against liver cancer
Date:9/8/2009

PHILADELPHIA Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

Findings of this phase II, multi-institutional study are published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"These results may not be practice changing, but they do emphasize the need to continue developing strategies targeting epidermal growth factor receptor [EGFR] in hepatocellular carcinoma," said lead researcher Tanios Bekaii-Saab, M.D., assistant professor of medicine and pharmacology and medical director of gastrointestinal oncology at the Ohio State University Comprehensive Cancer Center.

The prevalence of hepatocellular carcinoma is increasing worldwide, and since this form of cancer typically responds poorly to chemotherapy, new treatments are necessary to help curb its rise. The current standard treatment for advanced hepatocellular carcinoma is sorafenib.

This study is one of the first trials to test the tolerability and efficacy of lapatinib in patients with advanced hepatocellular carcinoma. Lapatinib targets both EGFR and Human EGFR type 2 (HER2/neu) signaling pathways. The FDA approved this drug in March of 2007 for patients with breast cancer who were already using the chemotherapeutic agent capecitabine. Lapatinib works by inhibiting the tyrosine kinase activity associated with the two oncogenes EGFR and HER2/neu.

Twenty-six patients with advanced hepatocellular carcinoma received 1,500 mg/d of lapatinib by mouth for 28 days. Bekaii-Saab and colleagues evaluated tumor and blood specimens for expression of these signaling pathways.

Results indicated that lapatinib only benefited a subgroup of patients who developed a rash, which is an effect attributable to EGFR/HER1 inhibition. These patients tended to have a more favorable outcome and longer survival compared to the overall study population. The most common side effects were diarrhea in 73 percent of participants, nausea in 45 percent and rash in 42 percent.

"Our findings suggest a potential benefit from EGFR inhibition," said Bekaii-Saab. "Overall though, we were certainly hopeful that lapatinib would be more active and were somewhat disappointed by the results."

Samuel B. Ho, M.D., an editorial board member for Clinical Cancer Research, believes this study provides important information about the relevance of these signaling pathways in advanced hepatocellular carcinoma.

"The results support the fact that hepatocellular carcinomas are clinically and biochemically heterogeneous, and that certain subsets of hepatocellular carcinoma may respond differently than others, suggesting that larger trials with patients more likely to respond may show a definite survival benefit," said Ho. "However, the study failed to find a marker that could differentiate between tumors that may or may not be expected to respond."

Ho is the chief of gastroenterology section at the VA San Diego Healthcare System, and professor of medicine at the University of California, San Diego.

Furthermore, the results of this study represent an important step in the strategy for designing clinical studies for this form of cancer, according to Ho, and additional studies are needed. Specifically with lapatinib, it will be important to determine a way to identify those patients who are more likely to respond and include them in a larger trial.

"Given the complexity of the biology in hepatocellular carcinoma and essentially all other malignancies, we should not hope a single marker would be predicative; it makes more sense biologically to monitor multiple potentially relevant markers," said Ho.


'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New research shows how chronic stress worsens neurodegenerative disease course
5. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
6. Circulating fats kill transplanted pancreas cells, study shows
7. New Heart Pump Shows Promise in Trial
8. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
9. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lapatinib shows minimal effect against liver cancer
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a ... that pledges to solve many catastrophic issues within funding campaigns. KICKICO developers are ... typical notion of crowdfunding - the raising of funds through the power of many ...
(Date:6/25/2017)... ... June 25, 2017 , ... FCPX LUT Vintage Volume ... old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 different color-grade presets, giving ... distorted looks, vignettes and blurs to single out subjects, plus much more. FCPX LUT ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... ... CareSet Labs released the Root NPI Graph today at the 2017 ... version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally created ... the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by Trotter, ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus is ... among men in the U.S. and the third most common cause of cancer related death ... man in seven will be diagnosed with prostate cancer during his lifetime. Those at ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 More than 400 ... effort to help spread lessons learned from clinical research ... Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: ... second phase of the Bringing Research in Diabetes to ... commitment to helping people with diabetes effectively manage their ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
Breaking Medicine Technology: